SCHEMBL5830271

SCHEMBL5830271

Cc1[nH]c(/C=C2\C(=O)Nc3cccc(-c4ccncc4)c32)c(C)c1CC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.56
FGFR1 P11362 14/20 0.56
PDGFRB P09619 14/20 0.56
FLT3 P36888 6/20 0.56
FLT4 P35916 3/20 0.56
AURKB Q96GD4 3/20 0.56
RET P07949 3/20 0.56
AURKA O14965 2/20 0.56
FLT1 P17948 2/20 0.56
MAP4K2 Q12851 2/20 0.56
STK3 Q13188 2/20 0.56
ALK Q9UM73 2/20 0.56
GAK O14976 1/20 0.56
RPS6KA5 O75582 1/20 0.56
RPS6KA4 O75676 1/20 0.56
LATS1 O95835 1/20 0.56
CSNK2A2 P19784 1/20 0.56
MAP2K2 P36507 1/20 0.56
ZAP70 P43403 1/20 0.56
MAP2K1 Q02750 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5830274 1.00 KDR (0.56) KDRFGFR1PDGFRBFLT3FLT4
SCHEMBL5830178 0.91 KDR (0.69) KDRFGFR1PDGFRBFLT3FLT4
SCHEMBL1395367 0.91 KDR (0.69) KDRFGFR1PDGFRBFLT3FLT4
SCHEMBL5829865 0.85 ALK (0.54) KDRFGFR1PDGFRBFLT3FLT4
SCHEMBL5829867 0.85 ALK (0.54) KDRFGFR1PDGFRBFLT3FLT4
SCHEMBL7239345 0.79 KDR (0.41) KDRFGFR1PDGFRBFLT3FLT4
SCHEMBL4781166 0.79 FGFR1 (0.53) KDRFGFR1PDGFRBFLT3FLT4
SCHEMBL1395114 0.79 FGFR1 (0.53) KDRFGFR1PDGFRBFLT3FLT4
SCHEMBL5829811 0.78 FLT1 (0.69) KDRFGFR1PDGFRBFLT3FLT4
SCHEMBL5829809 0.78 FLT1 (0.69) KDRFGFR1PDGFRBFLT3FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053086-B2 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors SUGEN, INC. (US) 2006-05-30 US disclosed
US-20040097497-A1 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors SUGEN, INC. 2004-05-20 US disclosed
US-20020187978-A1 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors SUGEN, INC. 2002-12-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020187978-A1 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors CDK2, CDK20, CDK3 KDR 1114/4885FGFR1 785/4885PDGFRB 1332/4885
US-20040097497-A1 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors CDK2, CDK20, CDK3 KDR 1114/4885FGFR1 785/4885PDGFRB 1332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.